Chronic Lymphoblastic Leukemia

Personalized Cell Therapy Combined with Imbruvica Achieves Complete Remission in High Percentage of Chronic Lymphocytic Leukemia Patients (06-5-2017)

Combining the kinase inhibitor Imbruvica (ibrutinib) with an investigational personalized cellular therapy known as CTL119 can lead to complete remission in patients with high-risk chronic lymphocytic leukemia (CLL), according to new research from the Perelman... Continue Reading

Imbruvica® Effective in Newly Diagnosed and Recurrent Chronic Lymphocytic Leukemia (07-11-2016)

Imbruvica (ibrutinib) produces long-lasting anti-cancer responses among patients with newly diagnosed chronic lymphocytic leukemia (CLL), as well as those who have received prior therapies. These results were recently presented at the 2016 annual meeting... Continue Reading

Arzerra® Approved as Maintenance Therapy for Advanced CLL (02-29-2016)

The United States Food and Drug Administration (FDA) has approved Arzerra® (ofatumumab) as maintenance therapy for the treatment of advanced chronic lymphocytic leukemia (CLL). This product is already approved to treat patients with CLL who have not... Continue Reading

FDA Approves New Treatment Options for Low Grade Lymphomas and Chronic Lymphocytic Leukemia (08-25-2014)

Gilead Sciences has confirmed FDA approval of Zydelig (idelalisib) for relapsed chronic lymphocytic leukemia (CLL), follicular lymphoma (FL) and small lymphocytic lymphoma (SLL). Non-Hodgkin’s lymphoma (NHL) is a form of cancer that begins in the cells... Continue Reading

Gazyva/Chlorambucil Improves Outcomes in Older CLL Patients with Other Health Problems (12-16-2013)

Among older people with chronic lymphocytic leukemia (CLL) and other health problems, initial treatment with Gazyva® (obinutuzumab) and chlorambucil was more effective than treatment with Rituxan® (rituximab) and chlorambucil. These results were presented... Continue Reading

Ibrutinib Active In Untreated, Relapsed and Unresponsive CLL (06-3-2013)

The drug ibrutinib was well tolerated and highly effective in patients with untreated, relapsed and unresponsive chronic lymphocytic leukemia—leading to large reductions in tumor burden, according to the results of a study presented at the American... Continue Reading

Lymphoma Patients and Transplant Recipients at Higher Risk of Melanoma (10-11-2012)

Individuals with lymphoma or those who have undergone organ transplants are far more likely than the average person to develop—and die from—melanoma, according to the results of a review published in Mayo Clinic Proceedings. Melanoma is a potentially... Continue Reading

Combination of Campath and Fludarabine Provides Benefit in CLL (02-16-2012)

Among people with previously treated, relapsed or refractory chronic lymphocytic leukemia (CLL), treatment with a combination of Campath® (alemtuzumab) and fludarabine results in better outcomes than treatment with fludarabine alone. These results were... Continue Reading

Many Patients with “Chemo Brain” Recover within Five Years (05-23-2011)

A study of “chemo brain”—the foggy thinking and forgetfulness that patients may experience after chemotherapy—suggests that the condition improves substantially over time for a majority of patients. For some patients, however, symptoms may persist... Continue Reading

Survivors of Some Childhood Cancers May Face Cognitive Impairment (05-18-2010)

Survivors of non-central nervous system (CNS) childhood cancers reported a statistically and clinically significantly higher rate of neurocognitive impairment than their cancer-free siblings, according to the results of a study published in the Journal... Continue Reading

Next Page »